[Special Stock] Lunit Rises 10% on News Proving Predictability of Anticancer Treatment
Medical artificial intelligence (AI) solution developer Lunit is showing strong performance on the 7th.
At 10:09 AM on this day, Lunit was trading at 108,600 KRW, up 10,200 KRW (10.37%) from the previous trading day.
Hot Picks Today
!["Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①](https://cwcontent.asiae.co.kr/asiaresize/93/2026051414165763158_1778735817.jpg)
"Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①
- "If That's the Case, Why Not Just Buy Stocks?" ETFs in Name Only, Now 'Semiconductor-Heavy' and a Playground for Short-Term Traders
- [Breaking] Two Days Before Strike... Central Labor Relations Commission Chair Park Soogeun Says "Differences Narrowing... Possibility of Agreement"
- Individual Investors Absorb Foreign Sell-Off... Concerns Over Becoming "Cannon Fodder" Emerge
- "No Cure Available, Spread Accelerates... Already 105 Dead, American Infected"
Lunit announced that at the American Society of Clinical Oncology (ASCO 2023) held in Chicago, USA from the 2nd to the 6th (local time), it demonstrated the potential use of LunitScope as a biomarker proving the treatment efficacy for patients with locally advanced rectal cancer (LARC).
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
